Waters stock jumped about 6% today, a sharp move for a steady life sciences instruments group, even though headline earnings showed a GAAP loss. The market is cheering one thing above all else: revenue surged to US$1.645b in the quarter, with the newly acquired Biosciences and Diagnostic Solutions businesses contributing US$817m and folding into the story faster than many expected.

The emotional gap is clear. Traders are reacting to proof that Waters can grow a much larger platform, while the income statement still reflects acquisition costs and purchase accounting noise that pushed reported EPS into a loss. The real test is whether this early integration momentum proves durable. That is what the rest of the numbers will help you judge.

Is Waters stock starting to look mispriced after strong revenue, a reported loss, and a higher P/S multiple than peers, or is the market still too cautious? See how those signals line up in our valuation analysis for Waters

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$1,645 million vs. US$771.332 million (very large increase in reported revenue, driven by the Biosciences and Diagnostic Solutions acquisition).
• Net Income/Loss, Q2 2026 vs. Q2 2025: loss of US$136 million vs. profit of US$147.111 million (swing into loss year on year).
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$1.38 per share vs. profit of US$2.47 per share (sharp decline in reported earnings per share).
• Free Cash Flow, Q2 2026 vs. prior quarter Q1 2026: US$202 million vs. not disclosed for Q1 2026 (positive free cash generation in a quarter that reported a GAAP loss).

Prefer clear visuals over digging through dense earnings tables and footnotes? See Waters' full financial picture, including a simple view of how its balance sheet lines up after the recent acquisition, in our interactive company report for Waters.

Evaluating Waters’ Bull Case On Integration And Growth

Bulls argue that Waters can turn the BD Biosciences and Diagnostic Solutions deal plus a richer workflow portfolio into a faster growing, higher quality business. This quarter provides some concrete milestones supporting that claim.

First, the core Waters engine is holding up. Organic revenue grew 7% reported and 9% in constant currency, with Analytical Sciences instruments, consumables and service all growing in the high single to low double digits. That supports the idea of a healthy installed base that can absorb new systems such as Alliance iS and Xevo TQ Absolute XR IVD, where IVD means in vitro diagnostics.

Second, the BD assets are not just along for the ride. They delivered US$817m in revenue with mid single digit growth and about a 400 bps acceleration versus the prior quarter trend, while free cash flow of US$202m shows the enlarged group is already cash generative even as GAAP EPS remains in a loss.

Reveal where the surface looks calm, but the models start to disagree on Waters' next big earnings inflection. Access the multi year revenue and EPS analyst estimates for Waters.

Waters Bear Case: Integration Fears Meet GAAP Reality

The bearish view is that Waters overpaid for BD Biosciences and Diagnostic Solutions and that integration risk will cap earnings, with any early strength proving temporary. This quarter does not fully clear that hurdle. Revenue from the acquired units reached US$817m with mid single digit growth and a 400 bps improvement versus the prior quarter trend, which pushes back on fears of outright stagnation. However, GAAP EPS moved into a loss of US$1.39 even as adjusted EPS landed at US$3.05.

That split is exactly what bears worry about. Acquisition costs and higher interest expense are still heavy enough to keep reported profit in the red. Management now describes Waters as a “sustainable high single digit” grower; however, EBIT margin guidance is flat and relies on US$200m run rate cost savings. For a cautious investor, several key proof points on clean earnings and margin expansion remain unmet.

After a swing from 21.6% to 3.6% profit margins and large one off items, it is worth asking whether Waters’ current GAAP loss and acquisition costs are the full story. Review our structured risk analysis for Waters which shows 3 important warning signs

Stay Ahead With Waters And Simply Wall St

If Waters is now on your radar after its sharp revenue move, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and spot a potential entry that fits your plan. After you own the stock, use the Portfolio Command Center to cut through noise and receive focused updates on earnings, balance sheet changes and key announcements. For a longer term view, tap into the Community to see how other investors are interpreting the same data and what they are watching next. By surfacing hidden catalysts and risks early, you give yourself a better chance to act with confidence and stay a step ahead of the market.

Seeking Alternatives Beyond Waters Stock?

Fresh stock ideas can gain breakout momentum fast and then slip from ideal entry zones. Scan these under the radar lists before the crowd catches up and act now.

• Jump on cash rich companies with solid balance sheets and steady fundamentals by scanning our curated list of solid balance sheet and fundamentals stocks (49 results).
• Spot income workhorses with yields that could help anchor your returns as prices move, using a hand picked set of 7 dividend fortresses.
• Chase early momentum in smaller AI players that already generate profits, not just hype, through a focused group of 68 profitable AI stocks that aren't just burning cash.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.